Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for weight loss or diabetes ... Sensitivity analyses looking at different GLP-1 RA doses relative to placebo yielded results ...

Further research is needed to explore the potential benefits of GLP-1 RAs for smoking cessation across different subgroups, including patients with obesity, she said. As this work is preliminary ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight ... following GLP-1RAs treatment. Overall, four different GLP-1RAs were investigated in the trials ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight ... following GLP-1RAs treatment. Overall, four different GLP-1RAs were investigated in the trials-liraglutide ...

"It will also be important to investigate the impact of GLP-1 RAs on different types of cancer ... nutritious eating and regular physical activity is "the foundation for cancer prevention and ...

GLP-1 receptor agonists (GLP-1 RAs), initially developed to manage type 2 diabetes, have garnered attention for their unexpected effects on women’s health. While these medications are known for ...

“Our results provide reassurance regarding the psychiatric safety profile of GLP-1 RAs and suggest that GLP-1 RA treatment is associated with improved mental well-being, in addition to the known ...

physical activity and psychological well-being are all addressed, often by a multi-disciplinary treatment team. From 2023, the GLP-1 drugs, initially liraglutide and later semaglutide, were ...

for GLP-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide. By applying AI to electronic health record (EHR) deidentified data within the Veradigm Network, researchers can now ...

Individuals with diabetes who require insulin can be a different group than those who do not require insulin,” Kim told Healthline. Glucagon-like peptide-1 receptor agonists (GLP-1s) work by ...

Data-driven clustering reveals distinct obesity phenotypes with unique clinical, behavioral, microbiome features, and differential GLP-1 responses. Some individuals with obesity have discordant ...